

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-53. (cancelled)

54. (withdrawn; currently amended) A method of treating SARS (Severe Acute Respiratory Syndrome) treatment, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts ~~and derivatives~~ to a subject in need of said treatment thereof.

55. (withdrawn; currently amended) A method of treating hemorrhagic fevers, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts ~~and derivatives~~ to a subject in need of said treatment thereof.

56. (withdrawn) The method according to claim 55 wherein fever is caused by Filovirus, Bunyavirus, Arenavirus or Flavivirus.

57. (withdrawn; currently amended) A method of treating viral diseases caused by viruses selected from the group

consisting of: Parainfluenza viruses, A, B and C influenza viruses; Respiratory Syncytial Virus; Reovirus; Rotavirus; Coronavirus; Parvovirus; Adenovirus; Papovavirus; Papillomavirus; Poxvirus; and Filovirus, comprising administering an effective amount of INDO and its pharmaceutically acceptable salts ~~and derivatives~~ to a subject in need of said treatment thereof.

58. (withdrawn; currently amended) The method according to claim 54 wherein INDO salts ~~and derivatives~~ comprise alkali metal salts, alkaline earth metal salts, aluminium salts, zinc salts, ammonium salts, inorganic acid addition salts, and/or organic acid addition salts.

59. (withdrawn) The method according to claim 54 wherein said INDO is in the form of a veterinary medicine, agriculture product, or aquaculture product.

60. (withdrawn) The method according to claim 54 wherein INDO is administered at concentrations ranging between 10 and 1000 microM.

61. (withdrawn) Use according to claim 54, wherein INDO is administered at concentrations ranging between 100 and 400 microM.

62. (withdrawn) The method according to claim 54 wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents and or antioxidants.

63. (withdrawn) The method according to claim 54 wherein INDO is administered by the oral, rectal, nasal, topical, vaginal, parenteral routes.

64. (withdrawn; currently amended) The method according to claim 54 wherein INDO is administered in combination with a carrier that is able to penetrate [[BBB]] blood-brain barrier.

65. (currently amended) A pharmaceutical composition comprising ~~INDO~~ indomethacin (INDO) and/or salts ~~and/or derivatives~~ thereof in combination with pharmaceutically effective amounts of at least one compound comprising: Interferon, metals and corresponding salts ~~and/or derivatives~~, prostanoids, antiviral drugs; and/or corresponding mixtures for the treatment of diseases comprising: tissue cytoprotection, SARS, gastroenteritis, hemorrhagic fevers, respiratory diseases, diseases caused by Coronavirus, Parainfluenza viruses, Influenza

viruses, Respiratory Syncytial Virus, virus-caused neoplasias, viral encephalitis, viral diseases in general, and viral diseases caused by genetically modified viruses.

66. (currently amended) The composition according to claim 65, wherein INDO salts ~~and/or derivatives~~ comprise alkali metal salts, alkaline earth metal salts, aluminium salts, zinc salts, ammonium salts, inorganic acid addition salts, and/or organic acid addition salts.

67. (withdrawn) The composition according to claim 65, wherein prostanoids comprise: cyclopentenone prostanoids, PGA₁, PGA₂, PGJ₁, PGJ₂, delta¹²-PGJ₂, and/or 15-deoxy-delta^{12,14}-PGJ₂.

68. (currently amended) The composition according to claim 65, wherein the metals comprise: zinc, gold, selenium, bismuth and/or cadmium, or corresponding salts ~~and/or derivatives~~.

69. (currently amended) The composition according to claim 65, wherein the metal salts ~~and/or derivatives~~ comprise: chloride, sulfate, lactate, citrate, iodate, maleate, thiomaleate, diethyl-dithiocarbamate, butyl salicilate, fumarate, succinate, and/or porphirin tetrakis metachloride.

70. (currently amended) The composition according to claim 65, wherein the metal is Zn and/or corresponding salts ~~and/or derivatives~~ comprise: ZnCl_2 , Zn sulfate, Zn lactate, Zn iodate, Zn diethyl-dithiocarbamate, Zn butyl salicylate, and/or Zn porphyrin tetrakis metachloride.

71. (withdrawn) The composition according to claim 65, wherein said antiviral drugs comprise: Ribavirin, acyclovir, amantadine, rimantadine, influenza virus neuroaminidase inhibitors, idoxuridine, fosfonacetic acid, AZT, DDC, and/or viral protease inhibitors.

72. (withdrawn) The composition according to claim 71, wherein the viral protease inhibitors are HIV protease inhibitors.

73. (previously presented) The composition according to claim 65, wherein INDO is administered in combination with pharmaceutically acceptable carriers comprising: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents, and/or antioxidants.

74. (previously presented) The composition according to claim 65, wherein INDO is in an oral, rectal, nasal, topical, vaginal, or parenteral form.

75. (currently amended) The composition according to claim 65, wherein INDO is in combination with a carrier that is able to penetrate [[BBB]] blood-brain barrier.

76. (currently amended) The composition according to claim 65, further comprising a pharmaceutically acceptable ~~vector~~ carrier.

77. (currently amended) A pharmaceutical composition comprising INDO in combination with a pharmaceutically effective amount of at least one metal and/or corresponding salts ~~and/or derivatives~~.

78. (currently amended) The composition according to claim 65, wherein the metals comprise: gold, selenium, or bismuth, and/or corresponding salts ~~and/or derivatives~~.